Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bora Lim

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatmentBora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Nature|March 25, 2021
Breast tumours maintain a reservoir of subclonal diversity during expansionDarlan C Minussi, Michael D Nicholson, Hanghui Ye, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
JCO Precision Oncology|March 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic ChemotherapyHiroko Masuda, Kenichi Harano, Sakiko Miura, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Cancer Discovery|January 21, 2025
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast CancerRahat Alam, Anna Reva, David G Edwards, et al.
Cell Metabolism|June 17, 2023
Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenationYaohua Zhang, Zilong Zhao, Lisa A Huang, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
JAMA Oncology|June 8, 2018
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast CancerNaoko Matsuda, Xiaoping Wang, Bora Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|May 18, 2019
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatmentBora Lim, Rashmi K Murthy, Jangsoon Lee, et al.
Nature|March 25, 2021
Breast tumours maintain a reservoir of subclonal diversity during expansionDarlan C Minussi, Michael D Nicholson, Hanghui Ye, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
JCO Precision Oncology|March 16, 2022
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic ChemotherapyHiroko Masuda, Kenichi Harano, Sakiko Miura, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
Cancer Discovery|January 21, 2025
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast CancerRahat Alam, Anna Reva, David G Edwards, et al.
Cell Metabolism|June 17, 2023
Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenationYaohua Zhang, Zilong Zhao, Lisa A Huang, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
JAMA Oncology|June 8, 2018
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast CancerNaoko Matsuda, Xiaoping Wang, Bora Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Pageof 15